Verrica Pharmaceuticals Achieves 130% YCANTH Revenue Growth in 2025, Expands Global Pipeline, and Extends Cash Runway into 2027
Verrica Pharmaceuticals Reports Q4 and FY 2025 Financial Res...
Sign in to continue:
Verrica Pharmaceuticals Reports Q4 and FY 2025 Financial Res...
Driven Brands Holdings Inc. Announces Amendment to Base Inde...
Cintas to Acquire UniFirst: Detailed Investor Analysis ...
SLB Provides Update on Middle East Operations and First Quar...
Lifeward Ltd. Regains Compliance with Nasdaq Minimum Bid Pri...
Portillo's Inc. Announces Major Leadership Transition: Eugen...
Tredegar Corporation Reports Fourth Quarter and Full Year 20...
Marpai, Inc. Issues \$250,000 Promissory Note to CEO - Inves...
Wingstop Inc. Announces Additional \$300 Million Share Repur...
Nauticus Robotics, Inc. Announces Issuance of Convertible De...